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Diabetic impairments in NO-
mediated endothelial progenitor 
cell mobilization and homing are 
reversed by hyperoxia and SDF-1α
Poor wound healing in diabetic patients is characterized by 
impaired angiogenesis and vasculogenesis. Th e bone marrow-
derived endothelial progenitor cell (EPC) is a key cell involved 
in vasculogenesis and homes to peripheral tissue in response 
to ischemia. Previous studies have begun to elucidate the 
mechanisms responsible for the mobilization of EPCs into 
the circulation and their recruitment into areas of peripheral 
tissue ischemia. However, it remains unknown why the main 
physiological stimulus for EPC mobilization and recruitment 
(that is, ischemia) fails to induce therapeutic EPC-mediated 
neovascularization and healing in wounds of diabetic hosts.
It is known that the EPC mobilization cascade starts with 
peripheral hypoxia-induced tissue release of vascular endothelial 
growth factor-A and subsequent activation of bone marrow 
stromal nitric oxide synthase (NOS), resulting in increased bone 
marrow nitric oxide (NO) levels. Th is results in the mobilization 
of EPCs from the bone marrow to circulation, allowing for their 
participation in tissue-level vasculogenesis. At the tissue level, 
EPC recruitment depends on ischemia-induced upregulation of 
stromal cell-derived factor-1α (SDF-1α).
In a recent study, Gallagher et al. examined the eff ect of 
diabetes in these processes. Th ey found that diabetic mice had 
impaired phosphorylation of endothelial NOS in the bone 
marrow, decreased circulating EPCs, and diminished SDF-
1α expression in cutaneous wounds (Figure). Interestingly, 
hyperoxia increased bone marrow NO and circulating EPCs, 
eff ects that were inhibited by the NOS inhibitor N-nitro-l-
arginine-methyl ester. In addition, administration of SDF-1α 
into wounds reversed the EPC homing impairment and, with 
hyperoxia, synergistically enhanced EPC mobilization, homing, 
and wound healing. Th us, hyperoxia reversed the diabetic defect 
in EPC mobilization, and SDF-1α reversed the diabetic defect in 
EPC homing. (J Clin Invest 2007; 117: 1249–1259)
Juan Oliver
Angiotensin II upregulates soluble 
epoxide hydrolase
Arachidonic acid can be converted to eicosanoids by three 
major enzymatic pathways: cyclooxygenase, lipoxygenase, and 
CYP 450 epoxygenase. Four epoxyeicosatrienoic acids (EETs) 
are the major metabolites generated by CYP 450 epoxygenase. 
EETs in endothelial cells exert autocrine eff ects but can also act 
as paracrine mediators on neighboring cells such as vascular 
smooth muscle cells. EETs exert many other eff ects; they can 
function as endothelium-derived hyperpolarizing factors and by 
increasing intracellular Ca2+ concentration in vascular smooth 
muscle and activate large-conductance Ca2+-activated K+ 
channels, causing hyperlocalization and lowering blood pressure.
Under physiological conditions, EETs can be enzymatically 
hydrolyzed to dihydroxyeicosatrienoic acids by epoxide 
hydrolases (EHs). Two major EHs exist in mammalian cells: 
soluble EH (sEH), which primarily presents in the cytosol 
and peroxisomes, and microsomal EH, which binds to the 
intracellular membranes. Soluble EH is highly expressed in 
the liver, kidney, intestine, and vasculature. In past studies, 
administration of selective inhibitors of sEH to angiotensin 
II-infused hypertensive rats greatly increased the level of EETs 
and lowered systolic blood pressure. In addition, a selective sEH 
inhibitor also reversed the hypertension in the spontaneously 
hypertensive rat. Th us, augmentation of EET levels by sEH 
seems to control blood pressure in vivo.
To examine the interaction between angiotensin II and EETs, 
Ai et al. treated endothelial cells with angiotensin II and found 
increased sEH expression (Figure). Transient transfection assays 
showed that the activity of the human sEH promoter increased 
Decreased SDF-1α expression in peripheral wounds of diabetic mice. 
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The level of sEH protein is elevated in the aortic intima of spontaneously 
hypertensive rats. 
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in endothelial cells in response to the hormone. Analysis of the 
promoter region of the sEH gene demonstrated that angiotensin 
II activates the sEH promoter through an activator protein-
1 (AP-1)-binding motif. Th ey also found elevated levels of 
sEH in the aortic intima of both spontaneously hypertensive 
rats and angiotensin II-infused normal rats. Further, losartan 
abolished the sEH induction. Th us, AP-1 activation is involved 
in the transcriptional upregulation of sEH by angiotensin 
II in endothelial cells, which may contribute to angiotensin 
II-mediated hypertension. (Proc Natl Acad Sci USA 2007; 104: 
9018–9023)
Juan Oliver
Bradykinin B1 and B2 receptors 
both have protective roles in renal 
ischemia/reperfusion injury
Angiotensin I-converting enzyme inhibitors (ACEIs) not only 
slow the progression of chronic renal diseases but are also 
protective aft er acute injury caused by ischemia/reperfusion 
in several organs, including the kidneys. Several observations 
indicate that the benefi cial eff ects of ACEIs in these acute models 
of disease are mainly due to activation of the bradykinin–nitric 
oxide cascade as a result of inhibition of the inactivation of 
bradykinin. Th us, ACEIs have a greater eff ect than angiotensin 
type I receptor antagonists, and both bradykinin B2 receptor 
(B2R) antagonists and NOS blockers markedly attenuate the 
acute protective eff ects of ACEIs.
 In mammals, at least two receptors have been identifi ed: the 
bradykinin B1 receptor (B1R) and the B2R. Th e stimulation 
of both receptors activates endothelial NOS in the vascular 
endothelium.
In contrast to the consensus that ACEIs have benefi cial 
eff ects on ischemia/reperfusion injury, previous studies have 
produced confl icting results concerning the eff ect of stimulating 
the two bradykinin receptors. To clarify these issues, Kakoki 
et al. generated mice lacking both the B1R and the B2R for 
comparison with wild-type mice and with mice lacking the 
B2R only. Th ey found that mortality rates, renal histological 
and functional changes, 8-hydroxy-2′-deoxyguanosine levels 
in total DNA, mitochondrial DNA deletions, and the number 
of TUNEL-positive cells in the kidneys increased progressively 
aft er 30 minutes of bilateral renal artery occlusion and 24 hours 
of reperfusion. Th e increases occurred in the following order 
(from lowest to highest): wild type, B2R-null, and B1RB2R-
null mice. Increases in mRNA levels of transforming growth 
factor-β1, connective tissue growth factor, and endothelin-1 
aft er ischemia/reperfusion injury were also exaggerated in the 
same order. Th us, both the B1 and the B2 bradykinin receptors 
play an important role in reducing DNA damage, apoptosis, 
morphological and functional kidney changes, and mortality 
during renal ischemia/reperfusion injury. (Proc Natl Acad Sci 
USA 2007; 104: 7576–7581)
Juan Oliver
Local angiotensin II generation in 
the subfornical organ increases 
drinking
Th e renin–angiotensin system is known to play a critical 
role in body fl uid regulation through its actions within the 
kidney and central nervous system. Direct intracranial or 
intracerebroventricular injection of angiotensin II causes 
increases in blood pressure and dipsogenic behavior. 
Furthermore, centrally administered angiotensin II receptor 
antagonists are known to eliminate the cardiovascular eff ects 
caused by exogenous hormone. Although these experiments 
have provided evidence that the central nervous system is a 
target for the pressor and dipsogenic actions of exogenous 
angiotensin II, it remains unclear how endogenous hormone 
is formed within the brain, where it is located, and how 
regional angiotensin II production correlates with specifi c 
cardiovascular responses.
In the brain, the subfornical organ (SFO) has long been 
known to be an important cardiovascular control region 
regulating fl uid homeostasis in response to angiotensin II. 
However, the SFO lies outside the blood–brain barrier and 
thus has access to circulating and intraventricular angiotensin. 
However, angiotensinogen (AGT) is abundantly expressed 
in the SFO. In a recent study, Sakai et al. examined the eff ects 
on fl uid homeostasis of regional production of angiotensin II 
derived from local renin (REN) and angiotensinogen in the 
SFO (Figure). Th ey used genetic techniques that allowed for 
spatiotemporal control of gene expression and ablation. Th ey 
found that targeted expression of hREN and hAGT resulted in 
a marked increase in water and salt intake, which signifi cantly 
decreased in response to the blockade of angiotensin receptors in 
the brain. Th e mice exhibited elevated angiotensin II, specifi cally 
in the SFO. SFO-specifi c ablation of hAGT synthesis by Cre 
recombinase resulted in a signifi cant decrease in hAGT and 
angiotensin II immunostaining in the SFO and correlated with 
a signifi cant decrease in water intake. Th ese results provide solid 
genetic evidence that local de novo synthesis of angiotensin II 
in the SFO plays an integral role in regulating fl uid homeostasis 
and thirst. (J Clin Invest 2007; 117: 1088–1095)
Qais Al-Awqati
 Localization of angiotensin peptide in the brain of SRA and SRAflox mice.
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